FcRn antagonist (antibody fragment)argenx

Efgartigimod

Efgartigimod is an FcRn antagonist that lowers circulating IgG, including pathogenic autoantibodies. It is approved in generalized myasthenia gravis and has been evaluated in other IgG-mediated diseases, including thyroid eye disease (the UplighTED program).

Also known as: VYVGART, ARGX-113

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Indications

Targets

Efgartigimod forecasting benchmarks

1 benchmark

ResolvedPhase 3

UplighTED (efgartigimod) Phase 3 in thyroid eye disease

Efgartigimod · Thyroid eye disease

Dec 15, 2025Clinical Trials

Mechanism & molecular targets

FcRn· gene

Indications studied

Thyroid eye disease· TED

Developed by

argenx· ARGX

About Efgartigimod

What is Efgartigimod?

What does Efgartigimod target?

Efgartigimod acts on Neonatal Fc receptor (FcRn).

How well do AI models predict Efgartigimod trial outcomes?

Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.